Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
31 studies found for:    " February 20, 2008":" March 21, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-Related Weight Loss
Conditions: HIV Infections;   Unintended Weight Loss;   Cachexia;   Anorexia;   AIDS Wasting Syndrome;   HIV Wasting Syndrome
Interventions: Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL;   Drug: Megestrol acetate oral suspension 40 mg/mL
2 Terminated Reactogenicity and Immunogenicity of Vaginal CNgp140
Conditions: HIV Infections;   Acquired Immune Deficiency Syndrome
Interventions: Biological: HIV glycoprotein CN54gp140 (vaccine);   Biological: Carbopol 974
3 Completed Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting;   HIV Infections
Interventions: Drug: Dronabinol;   Drug: Placebo
4 Completed Yoga for the Management of HIV-Metabolic Syndromes
Conditions: HIV Infections;   HIV Metabolic Cardiovascular Syndrome;   HIV Lipodystrophy;   HIV Metabolic Syndromes;   Hypertension
Interventions: Behavioral: Yoga lifestyle intervention;   Other: Standard of care
5 Completed Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
Conditions: HIV Infections;   HIV Positive;   Pregnant Women
Intervention:
6 Completed
Has Results
The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection
Condition: HIV Infection
Intervention: Drug: Tenofovir + emtricitabine  + raltegravir.
7 Completed
Has Results
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Conditions: HIV -1 Infection;   HIV Infections
Interventions: Drug: PRO 140 (humanized monoclonal antibody to CCR5);   Drug: Placebo Comparator
8 Completed HIV Prevention With the Mentally Ill
Condition: HIV Infections
Interventions: Behavioral: Skills Building with Motivational Interviewing;   Behavioral: Skills Building
9 Completed HORIZONS HIV Intervention
Conditions: HIV Infections;   Sexually Transmitted Diseases
Interventions: Behavioral: HORIZONS HIV Intervention;   Behavioral: enhanced standard-of-care
10 Completed Effectiveness of an Abstinence-Only HIV/Sexually Transmitted Disease Risk-Reduction Intervention for Young African-American Adolescents
Conditions: HIV Infections;   Sexually Transmitted Diseases
Interventions: Behavioral: Abstinence-only HIV/STD risk-reduction intervention;   Behavioral: Safer-sex-only HIV/STD risk-reduction intervention;   Behavioral: Long comprehensive HIV/STD risk-reduction intervention;   Behavioral: Short comprehensive HIV/STD risk-reduction intervention;   Behavioral: Health promotion control intervention
11 Completed Experimental Design of Couple Counseling and Testing in Antenatal Clinics in Dar es Salaam, Tanzania
Condition: HIV Infections
Interventions: Behavioral: Couples VCT;   Behavioral: Individual VCT
12 Active, not recruiting Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
Conditions: HIV Infections;   Staphylococcal Infections
Interventions: Drug: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%;   Drug: Placebo
13 Completed Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Conditions: Pregnancy;   HIV Infections;   Sexually Transmitted Diseases
Interventions: Behavioral: CenteringPregnancy Plus (CP+);   Behavioral: Usual care
14 Completed Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
Condition: HIV
Interventions: Drug: Maraviroc (UK-427,857);   Other: Placebo
15 Completed
Has Results
Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Conditions: HIV Infections;   Hyperlipidemia
Interventions: Drug: Pravastatin;   Drug: Darunavir;   Drug: Ritonavir;   Other: Washout
16 Completed Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
Condition: HIV Infections
Interventions: Drug: Maraviroc (UK-427,857);   Other: Placebo
17 Completed
Has Results
Raltegravir Intensification in HIV-infected Patients
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: Placebo
18 Completed An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
Condition: HIV Infections
Intervention: Drug: Emtricitabine
19 Completed Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda
Condition: HIV Infections
Interventions: Drug: Nevirapine;   Drug: HIV immune globulin solution
20 Completed Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Condition: HIV Infections
Interventions: Drug: EFV+TDF;   Drug: EFV+3TC+TDF

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Indicates status has not been verified in more than two years